Hybridoma Core Facility
Cleveland Clinic Lerner Research Institute, NB1-25
Earl Poptic, Facility Manager
Contact:
Serves: Investigators at the Lerner Research Institute
Overview
The Hybridoma Core provides a resource for both development and production of monoclonal antibodies, including consultation regarding all aspects of monoclonal antibody production such as epitope design. Services are performed under strict QC guidelines appropriate for antibodies that may have commercial potential. The core uses both stationary (T flasks) and suspension (roller bottle/spinner flasks) cultures for the production of monoclonal antibodies from hybridoma cell lines. Hybridoma cell lines can also be grown in Integra flasks, where the cells are maintained in a compartment separated from the media reservoir by a selective membrane, and the antibody is secreted in a relatively small volume of the extracapillary space. The advantage of this system is that the antibody is 50-100 fold more concentrated and of high purity. The Hybridoma Core Facility also offers polyclonal antibody production on a limited basis. The polyclonal antibodies are produced in rabbits, so capacity is determined by the availability of housing in the BRU (Animal Facility).
Page last updated: October, 2007
 |
216-445-6635
